Aurobindo Pharma USA will acquire Lannett from Lannett Seller Holdco for $250 million on a cash-free, debt-free basis.

In a market overshadowed by US tariff threats and a tumbling rupee, cautious trading is essential. This article outlines the ...

Elara Capital observes that Aurobindo Pharma has 14 biosimilars in the pipeline. The company has also filed 3 biosimilars for ...

Motilal Oswal is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in its ...

Indian pharmaceutical stocks traded under pressure on Wednesday after US President Donald Trump said he would sharply raise ...

Prabhudas Lilladher is bullish on Aurobindo Pharma has recommended buy rating on the stock with a target price of Rs 1300 in ...

In Q1 FY26, bookings surged 78% YoY/5x QoQ to Rs 114 billion (11% below estimate), fueled by healthy sales from the luxury ...

Recent hiccups related to manufacturing plant issues and tariff uncertainties have led to volatility in earnings and, ...

Aurobindo Pharma's consolidated net profit fell by 10.2% to ₹824 crore in Q1, despite a 4% increase in revenue driven by European and growth market sales.

Brokerage have shared views on multiple stocks today (August 6) post quarterly results. The top stocks that are on the radar of brokerages are: DLF, Adani Ports, Berger Paints, Aurobindo Pharma, ...

Following US President Trump's tariff announcement, Indian pharmaceutical and textile companies experienced significant stock ...